Jade Biosciences, Inc. Increase (Decrease) in Other Operating Liabilities
Jade Biosciences, Inc. (JBIO) reported Increase (Decrease) in Other Operating Liabilities of $202.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-04-25.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2025-04-25
- Jade Biosciences, Inc. increase (decrease) in other operating liabilities for the quarter ending 2025-03-31 was $202.00K, a 48.47% decline year-over-year.
- Jade Biosciences, Inc. increase (decrease) in other operating liabilities for the quarter ending 2024-12-31 was -$169.00K.
- Jade Biosciences, Inc. increase (decrease) in other operating liabilities for the quarter ending 2024-09-30 was $219.00K, a 97.30% increase year-over-year.
- Jade Biosciences, Inc. increase (decrease) in other operating liabilities for the quarter ending 2024-06-30 was -$279.00K.
- Jade Biosciences, Inc. increase (decrease) in other operating liabilities for fiscal 2024 was $163.00K.
- Jade Biosciences, Inc. increase (decrease) in other operating liabilities for fiscal 2023 was -$384.00K.
- Jade Biosciences, Inc. increase (decrease) in other operating liabilities for fiscal 2022 was -$133.00K.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 6 month | Increase (Decrease) in Other Operating Liabilities 9 month | Increase (Decrease) in Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2025-03-31 | $202.00K 10-Q · filed 2025-04-25 | $33.00K derived: sum of 2 quarters · filed 2025-04-25 | $252.00K derived: sum of 3 quarters · filed 2025-04-25 | -$27.00K derived: sum of 4 quarters · filed 2025-04-25 |
| 2024-12-31 | -$169.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $50.00K derived: sum of 2 quarters · filed 2025-03-27 | -$229.00K derived: sum of 3 quarters · filed 2025-03-27 | $163.00K 10-K · filed 2025-03-27 |
| 2024-09-30 | $219.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$60.00K derived: sum of 2 quarters · filed 2024-11-12 | $332.00K 10-Q · filed 2024-11-12 | $62.00K derived: sum of 4 quarters · filed 2025-04-25 |
| 2024-06-30 | -$279.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $113.00K 10-Q · filed 2024-08-12 | -$157.00K derived: sum of 3 quarters · filed 2025-04-25 | -$46.00K derived: sum of 4 quarters · filed 2025-04-25 |
| 2024-03-31 | $392.00K 10-Q · filed 2025-04-25 | $122.00K derived: sum of 2 quarters · filed 2025-04-25 | $233.00K derived: sum of 3 quarters · filed 2025-04-25 | -$1.00K derived: sum of 4 quarters · filed 2025-04-25 |
| 2023-12-31 | -$270.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$159.00K derived: sum of 2 quarters · filed 2025-03-27 | -$393.00K derived: sum of 3 quarters · filed 2025-03-27 | -$384.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $111.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$123.00K derived: sum of 2 quarters · filed 2024-11-12 | -$114.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$234.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$225.00K 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $9.00K 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | -$133.00K 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |